drugset / Trial / NCT04550260
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2020-10-19
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Capecitabine | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | fluorouracil | Small molecule | — | — |